While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

I've been following the developments around Ozempic and GLP-1 drugs with some interest for a while, and last week Eli Lilly launched its variant, Mounjaro, in India. Remember, India has the highest ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...